Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 6,251 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares in the company, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Evolus Stock Down 0.3 %

NASDAQ:EOLS traded down $0.04 during trading hours on Tuesday, reaching $11.99. 616,192 shares of the company traded hands, compared to its average volume of 618,998. The business's 50-day moving average price is $13.66 and its two-hundred day moving average price is $13.71. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market capitalization of $762.41 million, a P/E ratio of -13.18 and a beta of 1.28. Evolus, Inc. has a 1 year low of $9.25 and a 1 year high of $17.82.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays boosted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th.

Remove Ads

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Tang Capital Management LLC increased its position in shares of Evolus by 3.1% during the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock valued at $55,171,000 after acquiring an additional 150,000 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in Evolus by 10.8% during the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock valued at $34,557,000 after purchasing an additional 305,300 shares during the last quarter. Caligan Partners LP increased its holdings in shares of Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after purchasing an additional 498,900 shares in the last quarter. Millennium Management LLC raised its stake in shares of Evolus by 29.1% in the fourth quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock worth $15,107,000 after purchasing an additional 308,753 shares during the last quarter. Finally, Boothbay Fund Management LLC raised its stake in shares of Evolus by 30.9% in the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company's stock worth $14,217,000 after purchasing an additional 304,065 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.